Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
NEW YORK, April 26, 2017 -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that Dr. Lan Huang, Ph.D., Chairman and CEO, will present at Joseph Gunnar's Pioneers 2017 Conference on Tuesday, May 2, 2017 at 10:30 am ET in the Lotus East Room of the Mandarin Oriental Hotel, 80 Columbus Circle at 60th Street in New York City.
Investors attending the conference who wish to meet with management for a one-on-one meeting should notify their appropriate contact or e-mail [email protected].
For more information and registration, please visit the conference website.
About BeyondSpring
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
About Plinabulin
Studies on Plinabulin's method of action indicate that Plinabulin activates GEF-H1, a guanine nucleotide exchange factor. GEF-H1 activates downstream transduction pathways leading to the activation of the protein c-Jun. Activated c-Jun enters the nucleus of dendritic cells to upregulate immune-related genes, which contributes to the up-regulation of a series of genes leading to dendritic cell maturation, T-cell activation and other effects that prevent neutropenia.
Investor Relations: Garth Russell / Allison Soss KCSA Strategic Communications 212.896.1250 / 212.896.1267 [email protected] / [email protected] Media Relations: Caitlin Kasunich / Amy Singh KCSA Strategic Communications 212.896.1241 / 212.896.1207 [email protected] / [email protected]
